GSK plc (LON:GSK) Receives GBX 1,862.50 Average Price Target from Brokerages

GSK plc (LON:GSK) has received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is GBX 1,862.50 ($24.98).

GSK has been the subject of a number of analyst reports. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Friday, March 28th.

Insider Activity at GSK

In related news, insider Emma Walmsley sold 5,473 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.43), for a total transaction of £79,303.77 ($106,348.09). Also, insider Wendy Becker purchased 536 shares of GSK stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average cost of GBX 1,515 ($20.32) per share, with a total value of £8,120.40 ($10,889.63). 1.61% of the stock is owned by insiders.

GSK Price Performance

GSK stock opened at GBX 1,430.03 ($19.18) on Monday. GSK has a 1 year low of GBX 1,242.50 ($16.66) and a 1 year high of GBX 1,808.50 ($24.25). The company has a market cap of £58.03 billion, a P/E ratio of 23.10, a PEG ratio of 1.24 and a beta of 0.31. The firm has a 50-day moving average of GBX 1,405.41 and a 200 day moving average of GBX 1,394.90. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, sell-side analysts forecast that GSK will post 175.980975 EPS for the current year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.